A rationale-based methodology to address T cell manufacturing challenges, based on the intended final manufacturing process, proposes a robust, scalable, cost-effective, and sustainable allogeneic platform.
The successful outcomes delivered by cell and gene therapies, coupled with the emergence of modalities across nucleic acid therapeutics and microbiomes, pose the next scalability challenge.
While the first autologous cell therapy commercial products have shown tremendous clinical success, scaling out these therapies while considering individual patient processes is a new challenge.
Our development expertise across all gene therapy modalities (AAV, lentivirus, oncolytic virus, etc.) and proven clinical through commercial scale-up capabilities will provide full life cycle support of your life-saving therapeutic.
